Comment to: Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403 by Ellen van der Spek, René van der Griend

Get full text

Geriatric assessment in older patients with a hematologic malignancy: a systematic review by Ellen R.M. Scheepers, Ariel M. Vondeling, Noortje Thielen, René van der Griend, Reinhard Stauder, Marije E. Hamaker

Get full text

Thrombotic micro-angiopathy due to Strongyloides stercoralis hyperinfection by Manon C. Stam-Slob, Sef J.L.W. van den Beuken, René van der Griend, Lenneke E.M. Haas, Jeroen P.H.M. van den Wijngaard, Serena Slavenburg, Sanjay U.C. Sankatsing

Get full text

Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial by Simone Oerlemans, Lindy Paulina Johanna Arts, Jacobien M Kieffer, Judith Prins, Mels Hoogendoorn, Marjolein van der Poel, Ad Koster, Chantal Lensen, Wendy Bernadina Catharina Stevens, Djamila Issa, Johannes F M Pruijt, Margriet Oosterveld, René van der Griend, Marten Nijziel, Lidwine Tick, Eduardus F M Posthuma, Lonneke V van de Poll-Franse

Get full text

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients by Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene

Get full text